Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few stu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alborz Rahmani, Guglielmo Dini, Andrea Orsi, Laura Sticchi, Bianca Bruzzone, Alfredo Montecucco, Luca Pellegrini, Alessia Manca, Alexander Domnich, Angela Battistini, Bruno Kusznir Vitturi, Sonia Zacconi, Nicoletta Debarbieri, Giancarlo Icardi, Paolo Durando
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
COVID-19
mRNA vaccine
mass vaccination campaign
occupational health
healthcare workers
reactogenicity
Medicine
R
Acceso en línea:https://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f

Ejemplares similares